Feed - Buzzberg

13:00
Jul 30 ◎

LH FY2026 Q2 Watch

Labcorp Holdings Inc. (LH) FY2026 Q2 Earnings Call

RHHBY AZN LH ▾

Adam Schechter

Partnership to expand access to Roche's companion diagnostic; impacts prostate cancer treatment.

"We expanded nationwide access to Roche's FDA-approved companion diagnostic for people living with prostate cancer"

RHHBY WATCH

Adam Schechter

LabCorp's access expansion enables patients to qualify for AstraZeneca's targeted therapy.

"who may now be eligible for combination treatment with AstraZeneca's targeted therapy."

AZN WATCH

Adam Schechter

Guidance raised for revenue and EPS, driven by strong organic growth in both diagnostics and BLS, with continued margin expansion.

"LabCorp delivered another very strong quarter, driven by solid revenue growth, margin expansion, and progress across our strategic priorities."

LH WATCH

HIGH

13:00
Apr 30 ◎

LH FY2026 Q1 Watch

Labcorp Holdings Inc. (LH) FY2026 Q1 Earnings Call

ILMN AMZN MRK LH DGX ▾

Adam Schechter

LabCorp is expanding its oncology testing reach via partnership with Illumina, potentially driving more sequencing volume onto Illumina's platforms in community settings.

"As part of our growth in specialty areas, we collaborated with Illumina to broaden access to advanced genomic testing in oncology, particularly in community care settings."

ILMN WATCH

Adam Schechter

Collaboration uses AWS infrastructure for an AI real-world data platform, potentially increasing AWS usage in healthcare research.

"A new AI-powered real-world data platform being developed in partnership with Amazon Web Services and DataVant to accelerate Alzheimer's research."

AMZN WATCH

Adam Schechter

LabCorp's companion diagnostic supports wider use of Keytruda in a newly approved indication, potentially benefiting Merck's drug sales.

"We expanded nationwide access to the first FDA-approved companion diagnostics that helps identify platinum-resistant ovarian cancer patients who may benefit from Merck's Keytruda"

MRK WATCH

Adam Schechter

Management raised guidance for the year, citing strong volume growth and margin expansion across both segments, with a positive outlook on the specialty testing and partnership pipeline.

"Turning to our results, we're off to a strong start in 2026. with continued momentum in both our diagnostics and central laboratory businesses, and significant progress across our strategic growth priorities."

LH WATCH

Adam Schechter

Management expects the pipeline of hospital and regional lab deals to strengthen if PAMA goes into effect in January, as smaller labs will struggle to compete with scale players like LabCorp. — PAMA implementation could accelerate consolidation in the lab industry, benefiting large-scale players like LabCorp and Quest Diagnostics.

"if PAMA is implemented in January, although there will be a short-term impact during the year to us, I think over time it actually will increase the pipeline of deals because these local regional laboratories are under a lot of stress"

DGX WATCH

HIGH

14:00
Feb 17 ◎

LH FY2025 Q4 Watch

Labcorp Holdings Inc. (LH) FY2025 Q4 Earnings Call

ICLR RHHBY LH ▾

Julia Wong

LabCorp is reducing early development business by $50M revenue to streamline and increase operating income by Q2 2026. — Signals softening demand in early development (ED) segment, indicating competitive pressure across CROs; a retreat from ED suggests LabCorp sees better capital allocation elsewhere.

"we continue to focus on streamlining our business, which will reduce annual revenue by $50 million and increase operating income."

ICLR WATCH

Adam Schechter

Company installed new automated mass spectrometry system from Roche Diagnostics, signaling capex spend and automation shift. — This could provide Roche with a flagship reference site and competitive edge in lab automation, signaling potential share gains for Roche's diagnostics segment.

"LabCorp became the first US commercial laboratory to enter in an agreement to implement Roche's fully automated mass spectrometry solution."

RHHBY WATCH

Julia Wong

Management conveys strong confidence with positive guidance for 2026, driven by organic growth, launchpad savings, and improved margins, albeit with some headwinds from PAMA delay and ACA expirations fully incorporated.

"We expect full-year enterprise revenue growth of 5.4% at the midpoint of our guidance, improved margins across both segments, and adjusted EPS growth of approximately 9%."

LH WATCH

HIGH

Feed — Buzzberg